HCM vs. VTRS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at HCM and VTRS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
HCM trades as an American Depositary Receipt (ADR), offering U.S. investors a convenient way to access its foreign-listed shares. In contrast, VTRS is a standard domestic listing.
| Symbol | HCM | VTRS |
|---|---|---|
| Company Name | HUTCHMED (China) Limited | Viatris Inc. |
| Country | Hong Kong | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 2.73 billion USD | 12.42 billion USD |
| Exchange | NasdaqGS | NasdaqGS |
| Listing Date | March 16, 2016 | March 17, 1980 |
| Security Type | ADR | Common Stock |
Historical Performance
This chart compares the performance of HCM and VTRS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | HCM | VTRS |
|---|---|---|
| 5-Day Price Return | 0.16% | -0.37% |
| 13-Week Price Return | 18.50% | 21.58% |
| 26-Week Price Return | 24.64% | -1.39% |
| 52-Week Price Return | -- | -9.97% |
| Month-to-Date Return | -10.50% | 21.85% |
| Year-to-Date Return | 11.93% | -14.46% |
| 10-Day Avg. Volume | 19.33M | 11.82M |
| 3-Month Avg. Volume | 9.63M | 12.30M |
| 3-Month Volatility | 55.24% | 32.62% |
| Beta | 0.79 | 0.89 |
Profitability
Return on Equity (TTM)
HCM
37.02%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
In the upper quartile for the Pharmaceuticals industry, HCM’s Return on Equity of 37.02% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
VTRS
-19.92%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
VTRS has a negative Return on Equity of -19.92%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
HCM
77.53%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
HCM’s Net Profit Margin of 77.53% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
VTRS
-24.57%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
VTRS has a negative Net Profit Margin of -24.57%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
HCM
-3.27%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
HCM has a negative Operating Profit Margin of -3.27%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
VTRS
-26.54%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
VTRS has a negative Operating Profit Margin of -26.54%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | HCM | VTRS |
|---|---|---|
| Return on Equity (TTM) | 37.02% | -19.92% |
| Return on Assets (TTM) | 25.62% | -8.50% |
| Net Profit Margin (TTM) | 77.53% | -24.57% |
| Operating Profit Margin (TTM) | -3.27% | -26.54% |
| Gross Profit Margin (TTM) | 44.15% | 40.15% |
Financial Strength
Current Ratio (MRQ)
HCM
4.65
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
HCM’s Current Ratio of 4.65 is exceptionally high, placing it well outside the typical range for the Pharmaceuticals industry. This indicates a very strong liquidity position, though such a high ratio may also suggest that the company is not using its assets efficiently to generate profits.
VTRS
1.37
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
VTRS’s Current Ratio of 1.37 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
HCM
0.08
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
Falling into the lower quartile for the Pharmaceuticals industry, HCM’s Debt-to-Equity Ratio of 0.08 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
VTRS
0.82
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
VTRS’s Debt-to-Equity Ratio of 0.82 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
HCM
13.00
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
HCM’s Interest Coverage Ratio of 13.00 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
VTRS
-0.13
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
VTRS has a negative Interest Coverage Ratio of -0.13. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | HCM | VTRS |
|---|---|---|
| Current Ratio (MRQ) | 4.65 | 1.37 |
| Quick Ratio (MRQ) | 4.48 | 0.65 |
| Debt-to-Equity Ratio (MRQ) | 0.08 | 0.82 |
| Interest Coverage Ratio (TTM) | 13.00 | -0.13 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
HCM
0.00%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
HCM currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
VTRS
4.58%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
With a Dividend Yield of 4.58%, VTRS offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
HCM
0.00%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
HCM has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
VTRS
137.04%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
VTRS’s Dividend Payout Ratio of 137.04% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | HCM | VTRS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 4.58% |
| Dividend Payout Ratio (TTM) | 0.00% | 137.04% |
Valuation
Price-to-Earnings Ratio (TTM)
HCM
6.19
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
In the lower quartile for the Pharmaceuticals industry, HCM’s P/E Ratio of 6.19 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
VTRS
--
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for VTRS is currently unavailable.
Price-to-Sales Ratio (TTM)
HCM
4.80
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
HCM’s P/S Ratio of 4.80 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
VTRS
0.88
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
In the lower quartile for the Pharmaceuticals industry, VTRS’s P/S Ratio of 0.88 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
HCM
2.14
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
HCM’s P/B Ratio of 2.14 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
VTRS
0.67
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
VTRS’s P/B Ratio of 0.67 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | HCM | VTRS |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 6.19 | -- |
| Price-to-Sales Ratio (TTM) | 4.80 | 0.88 |
| Price-to-Book Ratio (MRQ) | 2.14 | 0.67 |
| Price-to-Free Cash Flow Ratio (TTM) | 88.93 | 7.29 |